Nursing Management of Diabetes Mellitus and Glycemic Disorders

Introduction

Diabetes mellitus is a chronic metabolic disorder characterized by persistent hyperglycemia resulting from defects in insulin secretion, insulin action, or both. Because insulin regulates carbohydrate, fat, and protein metabolism, uncontrolled diabetes can affect multiple body systems including the cardiovascular, renal, neurologic, and ocular systems. Acute complications such as diabetic ketoacidosis (DKA) and hyperosmolar hyperglycemic state (HHS) can rapidly become life-threatening if not recognized early. Long-term hyperglycemia leads to microvascular complications (retinopathy, nephropathy, neuropathy) and macrovascular disease (stroke, myocardial infarction). As nurses, continuous monitoring of blood glucose, HbA1c, electrolytes, and patient symptoms is critical to prevent both acute metabolic crises and long-term complications.

1️⃣ Glucose Regulation & Insulin Physiology 🧬

🔷 📘 Normal Glucose Homeostasis

• Pancreatic β-cells produce insulin in response to hyperglycemia.

• Insulin facilitates glucose uptake into muscle and adipose cells.

• Liver stores excess glucose as glycogen.

• Glucagon released when glucose ↓ below normal levels.

• Balance between insulin and glucagon maintains homeostasis.

• Normal fasting glucose 70–100 mg/dL (N: 70–100).

🔷 ⚙ Physiologic Mechanism

• Insulin binds cellular receptors → glucose transport activated.

• GLUT-4 transporters move glucose into cells.

• Insulin promotes glycogen synthesis in liver.

• ↓ hepatic glucose production during fed state.

• ↓ blood glucose levels after meals.

• Balanced endocrine signaling prevents hyperglycemia.

🔷 🩺 Laboratory Correlation (Normal)

• Fasting glucose 70–100 mg/dL (N: 70–100).

• HbA1c <5.7% (N: <5.7).

• C-peptide normal levels reflect insulin production.

• Insulin levels adequate during hyperglycemia.

• Stable electrolyte levels maintained.

• Normal glucose tolerance during oral glucose test.

🔷 💊 Clinical Nursing Relevance

• Monitor glucose levels in hospitalized patients.

• Recognize early hyperglycemia symptoms.

• Understand insulin pharmacodynamics.

• Identify risk factors for insulin resistance.

• Early detection prevents metabolic complications.

• Patient education essential for glucose control.

2️⃣ Type 1 Diabetes Mellitus 🧫

🔷 📘 Definition & Risk Factors

• Autoimmune destruction of pancreatic β-cells.

• Leads to absolute insulin deficiency.

• Usually diagnosed in childhood or adolescence.

• Genetic predisposition with environmental triggers.

• Viral infections may trigger immune response.

• Lifelong insulin therapy required.

🔷 ⚙ Pathophysiology

• Autoantibodies attack β-cells.

• Insulin secretion progressively declines.

• ↓ glucose uptake by cells → hyperglycemia.

• Body breaks down fat for energy.

• Ketone production increases.

• Risk of diabetic ketoacidosis (DKA).

🔷 🩺 Diagnostics / Clinical Findings

• ↑ fasting glucose ≥126 mg/dL (N: 70–100).

• ↑ HbA1c ≥6.5% (N: <5.7).

• Polyuria, polydipsia, polyphagia classic symptoms.

• Weight loss despite increased appetite.

• Positive autoantibodies (GAD) present.

• Low or absent C-peptide levels.

🔷 💊 Management & Nursing Priorities

• Lifelong insulin therapy required.

• Frequent blood glucose monitoring.

• Educate patient about hypoglycemia symptoms.

• Balanced carbohydrate intake recommended.

• Monitor for DKA symptoms.

• Early intervention prevents acute metabolic crises.

3️⃣ Type 2 Diabetes Mellitus 🍬

🔷 📘 Definition & Risk Factors

• Chronic metabolic disorder with insulin resistance.

• Most common form of diabetes.

• Strong association with obesity and sedentary lifestyle.

• Genetic predisposition increases susceptibility.

• Age >40 years increases risk.

• Metabolic syndrome frequently present.

🔷 ⚙ Pathophysiology

• Peripheral tissues become resistant to insulin.

• Pancreas initially increases insulin production.

• Over time β-cell dysfunction develops.

• Persistent hyperglycemia occurs.

• Hepatic glucose production increases.

• Chronic hyperglycemia damages blood vessels.

🔷 🩺 Diagnostics / Clinical Findings

• ↑ fasting glucose ≥126 mg/dL (N: 70–100).

• ↑ HbA1c ≥6.5% (N: <5.7).

• ↑ random glucose ≥200 mg/dL with symptoms.

• Often asymptomatic early stages.

• Obesity and hypertension common.

• Elevated triglycerides may be present.

🔷 💊 Management & Nursing Priorities

• Lifestyle modification primary treatment.

• Weight reduction improves insulin sensitivity.

• Oral antidiabetic medications initiated.

• Insulin therapy if glucose uncontrolled.

• Monitor HbA1c every 3 months.

• Education prevents long-term complications.

4️⃣ Diagnostic Criteria for Diabetes 📊

🔷 📘 Standard Diagnostic Thresholds

• Fasting glucose ≥126 mg/dL (N: 70–100).

• Random glucose ≥200 mg/dL with symptoms.

• HbA1c ≥6.5% (N: <5.7) diagnostic threshold.

• Oral glucose tolerance test ≥200 mg/dL.

• Prediabetes defined by impaired glucose tolerance.

• Screening recommended for high-risk patients.

🔷 ⚙ Physiologic Interpretation

• Persistent hyperglycemia indicates insulin dysfunction.

• Elevated HbA1c reflects chronic glucose exposure.

• Post-prandial spikes suggest insulin resistance.

• Impaired fasting glucose indicates early disease.

• Abnormal OGTT reveals glucose intolerance.

• Early diagnosis prevents long-term complications.

🔷 🩺 Clinical Indicators

• Polyuria from osmotic diuresis.

• Polydipsia due to dehydration.

• Polyphagia from cellular glucose deficiency.

• Fatigue and blurred vision common.

• Recurrent infections possible.

• Slow wound healing observed.

🔷 💊 Nursing Responsibilities

• Screen high-risk populations regularly.

• Educate patients on glucose monitoring.

• Promote lifestyle modification programs.

• Monitor laboratory trends carefully.

• Early referral to diabetes specialists.

• Prevent complications through education.

5️⃣ Diabetic Ketoacidosis (DKA) ⚠

🔷 📘 Definition & Risk Factors

• Acute metabolic emergency due to absolute insulin deficiency.

• Most common in Type 1 diabetes mellitus.

• Triggered by infection, missed insulin doses.

• Trauma, surgery, or stress may precipitate.

• Newly diagnosed diabetes may present as DKA.

• Rapid progression if untreated.

🔷 ⚙ Pathophysiology

• Insulin deficiency → glucose cannot enter cells.

• Cells use fat breakdown for energy.

• Fat metabolism produces ketone bodies.

• ↑ ketones → metabolic acidosis develops.

• Severe osmotic diuresis → dehydration.

• Electrolyte loss worsens metabolic imbalance.

🔷 🩺 Diagnostics / Clinical Findings

• ↑ glucose >250 mg/dL (N: 70–100).

• ↓ pH <7.30 (N: 7.35–7.45) metabolic acidosis.

• ↓ bicarbonate <18 mEq/L (N: 22–26).

• Positive serum or urine ketones.

• Kussmaul respirations deep rapid breathing.

• Fruity acetone breath odor present.

🔷 💊 Management & Nursing Priorities

• Rapid IV fluid resuscitation (normal saline).

• Continuous IV insulin infusion.

• Monitor potassium (N: 3.5–5.0 mEq/L) closely.

• Replace electrolytes as needed.

• Frequent glucose monitoring hourly.

• Treat underlying cause such as infection.

6️⃣ Hyperosmolar Hyperglycemic State (HHS) 🌡

🔷 📘 Definition & Risk Factors

• Severe hyperglycemic emergency without significant ketosis.

• Most common in Type 2 diabetes mellitus.

• Occurs in elderly or chronically ill patients.

• Triggered by infection or dehydration.

• Poor glucose control major contributor.

• Mortality higher than DKA if untreated.

🔷 ⚙ Pathophysiology

• Relative insulin deficiency prevents ketosis.

• Severe hyperglycemia develops.

• ↑ serum osmolarity causes cellular dehydration.

• Massive osmotic diuresis leads to fluid loss.

• Neurologic dysfunction may occur.

• Electrolyte imbalance worsens instability.

🔷 🩺 Diagnostics / Clinical Findings

• ↑ glucose >600 mg/dL (N: 70–100).

• ↑ serum osmolarity >320 mOsm/kg (N: 275–295).

• Minimal or absent ketones.

• Severe dehydration signs present.

• Neurologic symptoms: confusion or coma.

• ↑ BUN (N: 7–20) due to dehydration.

🔷 💊 Management & Nursing Priorities

• Aggressive IV fluid replacement initially.

• IV insulin infusion after fluid stabilization.

• Monitor electrolytes frequently.

• Correct dehydration carefully in elderly.

• Frequent neurologic assessment required.

• Treat precipitating cause promptly.

7️⃣ Hypoglycemia 🩸

🔷 📘 Definition & Risk Factors

• Blood glucose <70 mg/dL (N: 70–100).

• Common complication of insulin therapy.

• Missed meals after insulin administration.

• Excessive insulin dosing possible cause.

• Increased physical activity may trigger.

• Alcohol consumption increases risk.

🔷 ⚙ Pathophysiology

• Excess insulin lowers circulating glucose levels.

• Brain receives insufficient glucose supply.

• Sympathetic nervous system activated.

• Catecholamine release causes adrenergic symptoms.

• Severe hypoglycemia affects brain function.

• Untreated episodes may cause seizures or coma.

🔷 🩺 Diagnostics / Clinical Findings

• ↓ glucose <70 mg/dL (N: 70–100).

• Sweating and tremors present.

• Tachycardia and palpitations common.

• Confusion or irritability may occur.

• Severe cases cause seizures.

• Loss of consciousness possible.

🔷 💊 Management & Nursing Priorities

• If conscious → 15 g rapid carbohydrate.

• Recheck glucose after 15 minutes.

• Repeat treatment if glucose still low.

• IV dextrose 50% if unconscious.

• IM glucagon injection emergency treatment.

• Educate patients on hypoglycemia recognition.

8️⃣ Insulin Therapy & Types 💉

🔷 📘 Purpose & Indications

• Essential treatment for Type 1 diabetes.

• May be required in advanced Type 2 diabetes.

• Controls hyperglycemia by replacing insulin.

• Prevents acute metabolic emergencies.

• Improves long-term glucose control.

• Reduces microvascular complications.

🔷 ⚙ Mechanism of Action

• Insulin facilitates cellular glucose uptake.

• Stimulates glycogen storage in liver.

• Suppresses hepatic glucose production.

• Promotes protein synthesis.

• Decreases fat breakdown.

• Maintains metabolic homeostasis.

🔷 🩺 Common Insulin Types

• Rapid-acting: lispro, aspart onset 15 min.

• Short-acting: regular insulin onset 30–60 min.

• Intermediate: NPH onset 1–2 hours.

• Long-acting: glargine provides basal insulin.

• Duration varies among preparations.

• Combination regimens mimic physiologic insulin.

🔷 💊 Nursing Considerations

• Verify insulin type before administration.

• Monitor glucose levels regularly.

• Rotate injection sites to prevent lipodystrophy.

• Assess for hypoglycemia symptoms.

• Coordinate insulin with meal timing.

• Patient education essential for safety.

9️⃣ Non-Insulin Antidiabetic Medications 💊

🔷 📘 Biguanides – First-Line Therapy

• Metformin (Glucophage) first-line drug for Type 2 DM.

• ↓ hepatic glucose production → improved glycemic control.

• ↑ insulin sensitivity in muscle and adipose tissue.

• Does not cause hypoglycemia when used alone.

• May promote modest weight loss or weight neutrality.

• Contraindicated in renal failure (eGFR <30 mL/min) → lactic acidosis risk.

🔷 ⚙ Sulfonylureas & Meglitinides – Insulin Secretagogues

• Sulfonylureas: glipizide (Glucotrol), glyburide (DiaBeta), glimepiride (Amaryl).

• Stimulate pancreatic β-cells → ↑ insulin secretion.

• Risk for hypoglycemia and weight gain.

• Best for patients with residual β-cell function.

• Meglitinides: repaglinide (Prandin), nateglinide (Starlix).

• Short-acting insulin secretagogues taken before meals.

🔷 🧠 Insulin Sensitizers – Thiazolidinediones (TZDs)

• Pioglitazone (Actos), Rosiglitazone (Avandia).

• ↑ peripheral insulin sensitivity in muscle and fat.

• ↓ hepatic glucose production.

• Useful for insulin resistance states.

• Adverse effects: weight gain, fluid retention, heart failure risk.

• Monitor liver enzymes (AST/ALT N: <40 U/L) during therapy.

🔷 🩺 Incretin & Renal Glucose Modulators

• DPP-4 inhibitors: sitagliptin (Januvia), saxagliptin (Onglyza).

• ↑ incretin hormones → ↑ insulin secretion after meals.

• GLP-1 receptor agonists: liraglutide (Victoza), semaglutide (Ozempic).

• Delay gastric emptying → promote weight loss.

• SGLT2 inhibitors: empagliflozin (Jardiance), dapagliflozin (Farxiga).

• ↑ glucose excretion in urine → ↓ blood glucose levels.

🔟 Insulin Therapy 💉

🔷 📘 Rapid-Acting Insulin

• Lispro (Humalog), Aspart (NovoLog), Glulisine (Apidra).

• Onset 10–15 minutes, peak ~1 hour.

• Administer immediately before meals.

• Controls postprandial glucose spikes.

• Short duration reduces prolonged hypoglycemia risk.

• Often used in basal-bolus insulin regimens.

🔷 ⚙ Short-Acting Insulin

• Regular insulin (Humulin R, Novolin R).

• Onset 30–60 minutes, peak 2–4 hours.

• Only insulin used for IV infusion (DKA treatment).

• Administer 30 minutes before meals.

• Used in sliding scale insulin therapy.

• Monitor glucose frequently to prevent hypoglycemia.

🔷 🧠 Intermediate-Acting Insulin

• NPH insulin (Humulin N, Novolin N).

• Onset 1–2 hours, peak 6–12 hours.

• Provides basal insulin coverage.

• Often combined with rapid or short-acting insulin.

• Risk of nocturnal hypoglycemia due to peak action.

• Cloudy appearance → must roll vial gently before use.

🔷 🩺 Long-Acting & Ultra-Long Insulin

• Glargine (Lantus), Detemir (Levemir) long-acting.

• Degludec (Tresiba) ultra-long acting insulin.

• Provides 24-hour basal glucose control.

• No pronounced peak → lower hypoglycemia risk.

• Administer once daily at same time.

• Never mix glargine with other insulins.

9️⃣ Non-Insulin / Oral & Non-Insulin Antidiabetic Medications 💊

🔷 Biguanides – Metformin

• Metformin (Glucophage) first-line therapy for Type 2 diabetes.

• ↓ hepatic gluconeogenesis → ↓ fasting glucose.

• ↑ peripheral insulin sensitivity in muscle cells.

• Does not cause hypoglycemia when used alone.

• May promote weight neutrality or modest weight loss.

• Avoid if eGFR <30 mL/min, risk lactic acidosis.

🔷 Sulfonylureas – Insulin Secretagogues

• Glipizide (Glucotrol), Glyburide (DiaBeta), Glimepiride (Amaryl).

• Stimulate pancreatic β-cells → ↑ insulin secretion.

• Effective in early Type 2 diabetes.

• Risk of hypoglycemia if meals skipped.

• May cause weight gain.

• Monitor glucose (N: 70–100 mg/dL) regularly.

🔷 Meglitinides – Short-Acting Secretagogues

• Repaglinide (Prandin), Nateglinide (Starlix).

• Stimulate rapid insulin release after meals.

• Taken before each meal.

• Reduce postprandial glucose spikes.

• Short duration → lower hypoglycemia risk vs sulfonylureas.

• Skip dose if meal skipped.

🔷 Thiazolidinediones (TZDs)

• Pioglitazone (Actos), Rosiglitazone (Avandia).

• ↑ insulin sensitivity in muscle and adipose tissue.

• ↓ hepatic glucose production.

• Useful in insulin resistance states.

• May cause fluid retention and weight gain.

• Avoid in heart failure patients.

🔷 DPP-4 Inhibitors

• Sitagliptin (Januvia), Saxagliptin (Onglyza), Linagliptin (Tradjenta).

• ↑ incretin hormones → ↑ insulin secretion after meals.

• ↓ glucagon release.

• Improves postprandial glucose control.

• Low risk of hypoglycemia.

• Monitor for pancreatitis symptoms.

🔷 GLP-1 Receptor Agonists

• Liraglutide (Victoza), Semaglutide (Ozempic), Exenatide (Byetta).

• Injectable non-insulin therapy.

• ↑ insulin secretion and ↓ glucagon release.

• Delay gastric emptying → weight loss.

• Reduce appetite significantly.

• Risk: GI symptoms and pancreatitis.

🔷 SGLT2 Inhibitors

• Empagliflozin (Jardiance), Dapagliflozin (Farxiga), Canagliflozin (Invokana).

• Block renal glucose reabsorption in proximal tubules.

• ↑ glucose excretion in urine.

• ↓ blood glucose independently of insulin.

• Promote mild weight loss and BP reduction.

• Risk: UTI and genital infections.

🔷 Alpha-Glucosidase Inhibitors

• Acarbose (Precose), Miglitol (Glyset).

• Delay carbohydrate digestion in intestine.

• ↓ postprandial glucose spikes.

• Taken with first bite of meal.

• Common adverse effect: flatulence and diarrhea.

• Rarely causes hypoglycemia alone.

🔟 Insulin Therapy 💉

🔷 Rapid-Acting Insulin

• Lispro (Humalog), Aspart (NovoLog), Glulisine (Apidra).

• Onset 10–15 minutes, peak ~1 hour.

• Administer right before meals.

• Controls postprandial hyperglycemia.

• Used in basal-bolus insulin regimens.

• Monitor glucose to avoid hypoglycemia.

🔷 Short-Acting Insulin

• Regular insulin (Humulin R, Novolin R).

• Onset 30–60 minutes, peak 2–4 hours.

• Only insulin used IV for DKA treatment.

• Administer 30 minutes before meals.

• Used in sliding scale insulin therapy.

• Monitor glucose levels frequently.

🔷 Intermediate-Acting Insulin

• NPH insulin (Humulin N, Novolin N).

• Onset 1–2 hours, peak 6–12 hours.

• Provides basal insulin coverage.

• Often mixed with short-acting insulin.

• Risk of nocturnal hypoglycemia.

• Cloudy suspension → roll gently before use.

🔷 Long-Acting Insulin

• Glargine (Lantus), Detemir (Levemir).

• Provides steady basal insulin levels.

• Duration about 24 hours.

• No pronounced peak action.

• Lower risk of hypoglycemia overnight.

• Do not mix with other insulins.

🔷 Ultra-Long Acting Insulin

• Degludec (Tresiba) duration >42 hours.

• Provides stable basal glucose control.

• Flexible dosing schedule possible.

• Minimal peak reduces hypoglycemia risk.

• Used in once-daily basal regimens.

• Often combined with rapid insulin.

🔷 Premixed Insulin

• 70/30 NPH + Regular (Humulin 70/30).

• Combines basal and mealtime insulin.

• Simplifies insulin regimens for patients.

• Administer before breakfast and dinner.

• Risk of hypoglycemia if meals delayed.

• Useful in patients needing fewer injections.

🔷 Basal-Bolus Insulin Regimen

• Mimics physiologic insulin secretion pattern.

• Basal insulin maintains fasting glucose.

• Rapid insulin given before meals.

• Provides tight glycemic control.

• Common regimen in Type 1 diabetes.

• Requires frequent glucose monitoring.

🔷 Continuous Subcutaneous Insulin Infusion

• Insulin pump delivers continuous basal insulin.

• Bolus doses administered before meals.

• Uses rapid-acting insulin analogs.

• Allows precise glucose control.

• Requires patient education and monitoring.

• Reduces glycemic variability.

1️⃣1️⃣ Insulin Administration & Injection Sites 💉

🔷 📘 Common Injection Sites

• Abdomen fastest insulin absorption site.

• Upper outer arms moderate absorption rate.

• Anterior thighs slower insulin absorption.

• Upper buttocks slowest absorption area.

• Rotate sites to prevent lipodystrophy.

• Consistent site improves glucose control.

🔷 ⚙ Injection Technique

• Use subcutaneous tissue layer for insulin injection.

• Inject at 90° angle with short needles.

• Pinch skin fold in thin patients.

• Avoid injecting into scarred tissue.

• Rotate injection sites systematically.

• Prevents uneven insulin absorption.

🔷 🩺 Monitoring & Assessment

• Monitor glucose (N: 70–100 mg/dL fasting) regularly.

• Assess for lipohypertrophy at injection sites.

• Observe for bruising or infection signs.

• Monitor for hypoglycemia symptoms.

• Evaluate effectiveness through HbA1c (N: <5.7%).

• Ensure correct insulin dosing.

🔷 💊 Nursing Considerations

• Coordinate insulin administration with meals.

• Verify insulin type before injection.

• Double-check dose with another nurse if required.

• Educate patient on self-injection technique.

• Store insulin 2–8°C refrigerated if unopened.

• Prevent dosing errors and hypoglycemia.

1️⃣2️⃣ Self-Monitoring of Blood Glucose (SMBG) 🧪

🔷 📘 Purpose of Monitoring

• Tracks daily glucose control patterns.

• Helps adjust insulin or medication doses.

• Detects hyperglycemia or hypoglycemia early.

• Guides dietary and activity adjustments.

• Prevents acute diabetic complications.

• Supports long-term glycemic control.

🔷 ⚙ Physiologic Interpretation

• Fasting glucose reflects basal insulin activity.

• Post-meal glucose reflects insulin response.

• Persistent elevation indicates insulin resistance.

• Wide glucose variability increases complication risk.

• Tight glucose control reduces microvascular damage.

• Monitoring guides therapeutic adjustments.

🔷 🩺 Recommended Glucose Targets

• Fasting glucose 80–130 mg/dL target.

• Postprandial glucose <180 mg/dL goal.

• HbA1c <7% recommended for most adults.

• Severe hyperglycemia >250 mg/dL requires intervention.

• Hypoglycemia defined as <70 mg/dL.

• Frequent monitoring improves safety.

🔷 💊 Nursing Responsibilities

• Teach proper glucometer use.

• Ensure correct finger-stick technique.

• Rotate puncture sites on fingertips.

• Record glucose results accurately.

• Encourage patient self-management skills.

• Reinforce adherence to monitoring schedule.

1️⃣3️⃣ Diabetic Neuropathy 🧠

🔷 📘 Definition & Risk Factors

• Nerve damage caused by chronic hyperglycemia.

• Most common chronic diabetes complication.

• Risk increases with poor glucose control.

• Duration of diabetes major risk factor.

• Hypertension worsens nerve damage.

• Smoking accelerates neuropathy progression.

🔷 ⚙ Pathophysiology

• Chronic hyperglycemia damages small blood vessels.

• ↓ nerve oxygen supply → nerve ischemia.

• Sorbitol accumulation injures nerve fibers.

• Oxidative stress worsens neuronal injury.

• Peripheral sensory nerves affected first.

• Progressive nerve degeneration develops.

🔷 🩺 Diagnostics / Clinical Findings

• Numbness and tingling in feet.

• Burning pain or sharp shooting sensations.

• Loss of protective sensation.

• Reduced vibration perception.

• Foot ulcers may develop.

• Reflexes decreased in severe neuropathy.

🔷 💊 Management & Nursing Priorities

• Tight glucose control prevents progression.

• Medications: gabapentin, pregabalin for pain.

• Encourage daily foot inspection.

• Proper footwear prevents injury.

• Regular neurological assessment.

• Early treatment prevents ulcers and amputations.

1️⃣4️⃣ Diabetic Nephropathy 🚰

🔷 📘 Definition & Risk Factors

• Kidney damage from chronic hyperglycemia.

• Leading cause of chronic kidney disease.

• Risk increases with long-standing diabetes.

• Hypertension worsens renal damage.

• Smoking accelerates nephropathy progression.

• Genetic susceptibility contributes.

🔷 ⚙ Pathophysiology

• Hyperglycemia damages glomerular capillaries.

• Thickening of glomerular basement membrane.

• ↑ glomerular pressure damages filtration barrier.

• Protein leaks into urine.

• Progressive nephron loss occurs.

• Chronic kidney disease develops.

🔷 🩺 Diagnostics / Clinical Findings

• Microalbuminuria >30 mg/day (N: <30).

• ↑ creatinine >1.3 mg/dL (N: 0.6–1.3).

• ↑ BUN >20 mg/dL (N: 7–20).

• Hypertension often present.

• Edema in advanced disease.

• Declining GFR <60 mL/min indicates CKD.

🔷 💊 Management & Nursing Priorities

• Strict glucose control slows progression.

• ACE inhibitors protect renal function.

• Monitor urine albumin levels regularly.

• Control blood pressure <130/80 mmHg.

• Avoid nephrotoxic medications.

• Early intervention prevents dialysis.

1️⃣5️⃣ Diabetic Retinopathy 👁

🔷 📘 Definition & Risk Factors

• Microvascular damage to retinal blood vessels from chronic hyperglycemia.

• Leading cause of preventable blindness in adults.

• Risk increases with long duration of diabetes.

• Poor glycemic control accelerates retinal damage.

• Hypertension worsens retinal vascular injury.

• Pregnancy may accelerate retinopathy progression.

🔷 ⚙ Pathophysiology

• Chronic hyperglycemia damages retinal capillaries.

• Capillary leakage → microaneurysm formation.

• Retinal ischemia stimulates neovascularization.

• Fragile new vessels prone to bleeding.

• Retinal edema impairs visual acuity.

• Progressive retinal damage leads to blindness.

🔷 🩺 Diagnostics / Clinical Findings

• Blurred or fluctuating vision reported.

• Floaters or dark spots in vision.

• Fundoscopic exam shows microaneurysms and hemorrhages.

• Retinal edema may be present.

• Visual acuity gradually declines.

• Annual dilated eye examination recommended.

🔷 💊 Management & Nursing Priorities

• Maintain tight glucose control to slow progression.

• Control blood pressure aggressively.

• Laser photocoagulation prevents vision loss.

• Anti-VEGF injections reduce neovascularization.

• Encourage annual ophthalmologic screening.

• Early detection prevents irreversible blindness.

1️⃣6️⃣ Diabetic Foot & Ulcer Prevention 🦶

🔷 📘 Definition & Risk Factors

• Foot ulcers caused by neuropathy + poor circulation.

• Common complication of long-standing diabetes.

• Loss of protective sensation increases injury risk.

• Peripheral vascular disease worsens healing.

• Improper footwear contributes to ulcers.

• Smoking increases vascular complications.

🔷 ⚙ Pathophysiology

• Peripheral neuropathy → loss of sensation in feet.

• Repeated trauma goes unnoticed.

• Microvascular disease reduces tissue perfusion.

• Wound healing becomes impaired.

• Infection may spread rapidly.

• Severe cases lead to amputation risk.

🔷 🩺 Diagnostics / Clinical Findings

• Loss of vibration or pressure sensation.

• Foot ulcers or callus formation.

• Poor peripheral pulses.

• Delayed wound healing observed.

• Signs of infection possible.

• Skin dryness and cracking present.

🔷 💊 Management & Nursing Priorities

• Inspect feet daily for cuts or ulcers.

• Wear properly fitted footwear.

• Maintain good foot hygiene.

• Trim nails carefully to avoid injury.

• Prompt treatment of any foot wounds.

• Early intervention prevents amputation.

1️⃣7️⃣ Gestational Diabetes Mellitus (GDM) 🤰

🔷 📘 Definition & Risk Factors

• Glucose intolerance first recognized during pregnancy.

• Occurs due to pregnancy-related insulin resistance.

• Risk higher in obesity and family history of diabetes.

• Previous macrosomic infant increases risk.

• Advanced maternal age predisposes.

• Usually diagnosed during 24–28 weeks gestation.

🔷 ⚙ Pathophysiology

• Placental hormones cause insulin resistance.

• Maternal pancreas increases insulin production.

• Inadequate compensation leads to hyperglycemia.

• Glucose crosses placenta to fetus.

• Fetal pancreas produces excess insulin.

• Leads to fetal macrosomia.

🔷 🩺 Diagnostics / Clinical Findings

• Oral glucose tolerance test abnormal.

• 1-hour glucose ≥180 mg/dL screening result.

• Fasting glucose ≥95 mg/dL (N: <95 pregnancy).

• Often asymptomatic during pregnancy.

• Ultrasound may show large fetus.

• Excess amniotic fluid possible.

🔷 💊 Management & Nursing Priorities

• Dietary modification and glucose monitoring.

• Moderate exercise improves insulin sensitivity.

• Insulin therapy if diet insufficient.

• Monitor fetal growth carefully.

• Postpartum glucose reassessment required.

• Prevent maternal and fetal complications.

1️⃣8️⃣ Sick-Day Management in Diabetes 🌡

🔷 📘 Definition & Importance

• Special management during acute illness or infection.

• Stress hormones increase blood glucose levels.

• Risk of DKA or HHS increases during illness.

• Appetite often decreases.

• Medication adherence remains essential.

• Frequent monitoring required.

🔷 ⚙ Physiologic Response to Illness

• Infection triggers stress hormone release.

• Cortisol and catecholamines raise glucose levels.

• Insulin resistance increases during illness.

• Hyperglycemia may worsen dehydration.

• Ketone production increases in Type 1 diabetes.

• Risk of metabolic emergencies rises.

🔷 🩺 Monitoring Parameters

• Check glucose every 3–4 hours.

• Monitor ketones if glucose >250 mg/dL.

• Maintain hydration with fluids.

• Monitor temperature for infection.

• Observe for vomiting or dehydration.

• Seek care if glucose remains uncontrolled.

🔷 💊 Nursing & Patient Education

• Never stop insulin during illness.

• Maintain carbohydrate intake if possible.

• Drink fluids every hour to prevent dehydration.

• Seek medical care if vomiting persists.

• Educate patient on emergency warning signs.

• Early management prevents DKA or HHS.

1️⃣9️⃣ Macrovascular Complications of Diabetes ❤️

🔷 📘 Definition & Major Risks

• Long-term damage to large blood vessels from chronic hyperglycemia.

• Major cause of mortality in diabetes patients.

• Leads to coronary artery disease, stroke, peripheral artery disease.

• Hyperglycemia accelerates atherosclerosis formation.

• Dyslipidemia and hypertension worsen vascular damage.

• Smoking significantly increases cardiovascular risk.

🔷 ⚙ Pathophysiology

• Persistent hyperglycemia damages vascular endothelium.

• ↑ oxidative stress promotes plaque formation.

• LDL oxidation accelerates atherosclerosis.

• Narrowed arteries → ↓ tissue perfusion.

• Thrombosis risk increases.

• Leads to myocardial infarction or stroke.

🔷 🩺 Diagnostics / Clinical Findings

• ↑ LDL cholesterol >100 mg/dL (N: <100).

• ↓ HDL <40 mg/dL men / <50 women.

• ↑ triglycerides >150 mg/dL (N: <150).

• Hypertension >130/80 mmHg often present.

• Symptoms of angina or claudication.

• Abnormal ECG or stress test findings.

🔷 💊 Management & Nursing Priorities

• Strict glycemic control (HbA1c <7%) recommended.

• Statin therapy reduces cardiovascular risk.

• Control blood pressure <130/80 mmHg.

• Encourage regular physical activity.

• Smoking cessation essential.

• Lifestyle modification prevents vascular complications.

2️⃣0️⃣ Comprehensive Nursing Management in Diabetes 🩺

🔷 📘 Priority Assessment Focus

• Monitor blood glucose trends regularly.

• Assess for symptoms of hypo- and hyperglycemia.

• Monitor HbA1c every 3–6 months (goal <7%).

• Evaluate dietary habits and medication adherence.

• Assess weight, BMI, and blood pressure.

• Screen for complications during routine visits.

🔷 ⚙ Metabolic Monitoring

• Monitor glucose (N: 70–100 mg/dL fasting).

• Check HbA1c (N: <5.7%) periodically.

• Monitor lipid profile and renal function.

• Track creatinine (N: 0.6–1.3 mg/dL).

• Assess urine for microalbumin <30 mg/day (N: <30).

• Early detection prevents organ damage.

🔷 🩺 Complication Prevention

• Encourage routine eye examinations annually.

• Perform regular foot assessment.

• Maintain blood pressure control.

• Promote vaccination for infection prevention.

• Educate on wound care and infection signs.

• Early intervention prevents severe complications.

🔷 💊 Patient Education & Self-Management

• Teach proper medication adherence.

• Reinforce dietary carbohydrate control.

• Encourage regular physical activity.

• Educate on recognizing hypoglycemia symptoms.

• Stress importance of daily glucose monitoring.

• Empower patient self-management for long-term control.